Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)
Reference45 articles.
1. Pérez-Carbonell L, Mignot E, Leschziner G, et al. Understanding and approaching excessive daytime sleepiness. Lancet. 2022;400(10357):1033–46.
2. Lal C, Weaver TE, Bae CJ, et al. Excessive daytime sleepiness in obstructive sleep apnea: mechanisms and clinical management. Ann Am Thorac Soc. 2021;18(5):757–68.
3. Ono T, Takenoshita S, Nishino S. Pharmacologic management of excessive daytime sleepiness. Sleep Med Clin. 2022;17(3):485–503.
4. Baladi MG, Forster MJ, Gatch MB, et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2018;366(2):367–76.
5. TMC Pharma (EU) Ltd. Sunosi (solriamfetol) film-coated tablets: EU summary of product characteristics. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/sunosi. Accessed 6 Sep 2023.